HER3-DXd (Clinical Trial)
Funding Details
- Awarder
- RSS - www.prnewswire.com
- Date Award
- May 31, 2025
- Vertical
- Pharmaceuticals
- Funding URL
- View Funding Page
Company Info
- Traction
- The phase II TUXEDO-3 study has shown promising results, indicating potential for significant impact in the oncology market.
- Company Description
- HER3-DXd is a novel therapeutic agent showing promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options.
- Market
- Oncology
- Location
- USA